Despite of our seemingly contradictory findings, i.e., that IGF-I treatment induces Glioma cell motility, however, the same cells are resistant to the specific IGF-IR inhibitor; and that fenofibrate attenuates IGF-IR signaling responses, the fenofibrate treatment was still very effective in compromising glioma cell motility. The gene discussed is IGF1; the disease is central nervous system cancer.